选择三阴性癌症患者进行免疫治疗。

IF 2.4 4区医学 Q3 ONCOLOGY

Surgical Oncology Clinics of North America Pub Date : 2023-10-01 DOI:10.1016/j.soc.2023.05.005

Stephanie Downs-Canner MD , Elizabeth A. Mittendorf MD, PhD

引用次数: 0

摘要

术前免疫疗法与化疗相结合的批准是早期癌症三阴性患者的一个实践性进展。最佳的患者选择需要仔细注意分期和平衡潜在风险与预期收益，尤其是与免疫相关的不良事件有关的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Selecting Triple Negative Breast Cancer Patients for Immunotherapy

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Surgical Oncology Clinics of North America 医学-外科

CiteScore

3.90

自引率

0.00%

发文量

审稿时长

12 months

期刊介绍： Published four times each year—January, April, July, and October—Surgical Oncology Clinics of North America updates you on the latest trends in patient management, keeps you up to date on the newest advances, and provides a sound basis for choosing treatment options. Each issue focuses on a single topic in surgical oncology, including pancreatic cancer, radiation oncology, breast cancer, colorectal cancer, head and neck cancer, palliative care, gene therapy, sarcomas, cancer screening, treatment of colorectal cancer, biliary tract and primary liver tumors, breast cancer, imaging, and more.